Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.65 |
| ▸ | RELA | Q04206 | 2/20 | 0.65 |
| ▸ | FPR2 | P25090 | 12/20 | 0.59 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590253 | 1.00 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL590254 | 1.00 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL29935444 | 1.00 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL22956003 | 1.00 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL590256 | 1.00 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL590255 | 1.00 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL588778 | 0.94 | NFKB1 (0.61) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL588777 | 0.94 | NFKB1 (0.61) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL588776 | 0.94 | NFKB1 (0.61) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL588779 | 0.94 | NFKB1 (0.61) | NFKB1NFKB2RELAFPR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108486-A1 | SYNTHESIS OF PRO-RESOLVING ANALOGS AND COMPOSITIONS THEREFOR | NOCENDRA INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12527760-B2 | Synthesis of pro-resolving analogs and compositions therefor | NOCENDRA INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20220288005-A1 | SYNTHESIS OF PRO-RESOLVING ANALOGS AND COMPOSITIONS THEREFOR | NOCENDRA INC. (US) | 2022-09-15 | — | — | US | disclosed |
| EP-4003062-A1 | SYNTHESIS OF PRO-RESOLVING ANALOGS AND COMPOSITIONS THEREFOR | Nocendra Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527760-B2 | Synthesis of pro-resolving analogs and compositions therefor | ALOX15B, ALOX12, ALOX5 | NFKB1 2338/4885NFKB2 2710/4885RELA 3332/4885 |
| US-20220288005-A1 | SYNTHESIS OF PRO-RESOLVING ANALOGS AND COMPOSITIONS THEREFOR | ALOX15B, ALOX12, ALOX15 | NFKB1 1459/4885NFKB2 2228/4885RELA 2505/4885 |
| US-20260108486-A1 | SYNTHESIS OF PRO-RESOLVING ANALOGS AND COMPOSITIONS THEREFOR | ALOX15B, ALOX12, ALOX15 | NFKB1 3016/4885NFKB2 3399/4885RELA 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.